Menu

Sanctioned Psychiatrist Off Restriction

Charles Nemeroff, who was barred from receiving grants for 2 years in 2008, snags $401K from the NIH to study PTSD.

Aug 14, 2012
Jef Akst

In December 2008, psychiatrist Charles Nemeroff, then at Emory University, was sanctioned for not disclosing more than $1 million from drug companies to promote their products in academic publications. His punishment: Emory barred him from receiving grants for 2 years. But those 2 years have come and gone, and in May, the National Institutes of Health (NIH) awarded Nemeroff, now at the University of Miami, a 5-year, $401,675-a-year grant to study posttraumatic stress disorder.

Shortly after the grant was announced, however, Senator Charles Grassley (R-IA), an activist for public disclosure of financial relationships in the biomedical fields, wrote a letter to the NIH questioning the decision. “Please explain how the NIH arrived at this decision to award Dr. Nemeroff despite past ethical problems,” Grassley wrote. “Although NIH has recently revamped its conflict of interest guidelines, this decision risks sending the wrong message to physicians seeking or performing federally funded research.” Furthermore, he noted, the Department of Health and Human Services’s Office of Inspector General (OIG) and the Department of Justice (DOJ) have been collaborating on an investigation of Nemeroff, and the results of that query have yet to be released.

Earlier this month, NIH Deputy Director Lawrence Tabak responded to Grassley, the blog Pharmalot reported. He explained that peer reviewers weren't told about the OIG and DOJ investigations because they are confidential. "Absent any finding by the OIG or other actionable grounds at this time to exclude Dr. Nemeroff, the NIH followed standard procedures," Tabak wrote. In addition, the NIH specifically asked the University of Miami about potential conflicts of interest, noted that the research does not involve the testing of any drugs, and stated that a reviewer that used to work with Nemeroff (Thomas Insel, director of the National Institute of Mental Health) recused himself from the review process. "I want to assure you that all procedures have been followed carefully in the process of awarding this specific grant to the University of Miami," Tabak wrote.

(Hat tip to ScienceInsider.)

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.